0 XP   0   0   0

Mega Lifesciences Public Company Limited










Financial Health of Mega Lifesciences Public Company Limited




Comparing to competitors in the Drug Manufacturers-Specialty & Generic industry




  Industry Rankings  


Mega Lifesciences Public Company Limited
Buy, Hold or Sell?

Should you buy, hold or sell Mega Lifesciences Public Company Limited?

I guess you are interested in Mega Lifesciences Public Company Limited. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Mega Lifesciences Public Company Limited

Let's start. I'm going to help you getting a better view of Mega Lifesciences Public Company Limited. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is Mega Lifesciences Public Company Limited even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how Mega Lifesciences Public Company Limited is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Mega Lifesciences Public Company Limited. The closing price on 2022-12-02 was ฿46.00 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
Mega Lifesciences Public Company Limited Daily Candlestick Chart

Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

1.1. Profitability of Mega Lifesciences Public Company Limited.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Mega Lifesciences Public Company Limited earns for each ฿1 of revenue.

  • Above 10% is considered healthy but always compare Mega Lifesciences Public Company Limited to the Drug Manufacturers-Specialty & Generic industry mean.
  • A Net Profit Margin of 14.5% means that ฿0.14 for each ฿1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Mega Lifesciences Public Company Limited:

  • The MRQ is 14.5%. The company is making a huge profit. +2
  • The TTM is 15.3%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ14.5%TTM15.3%-0.8%
TTM15.3%YOY11.6%+3.6%
TTM15.3%5Y12.0%+3.2%
5Y12.0%10Y10.3%+1.7%
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ14.5%0.4%+14.1%
TTM15.3%0.3%+15.0%
YOY11.6%0.2%+11.4%
5Y12.0%-0.7%+12.7%
10Y10.3%-0.1%+10.4%
1.1.2. Return on Assets

Shows how efficient Mega Lifesciences Public Company Limited is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Mega Lifesciences Public Company Limited to the Drug Manufacturers-Specialty & Generic industry mean.
  • 3.9% Return on Assets means that Mega Lifesciences Public Company Limited generated ฿0.04 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Mega Lifesciences Public Company Limited:

  • The MRQ is 3.9%. Using its assets, the company is less efficient in making profit.
  • The TTM is 4.3%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ3.9%TTM4.3%-0.3%
TTM4.3%YOY3.5%+0.8%
TTM4.3%5Y3.4%+0.8%
5Y3.4%10Y3.0%+0.4%
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ3.9%0.1%+3.8%
TTM4.3%0.1%+4.2%
YOY3.5%-0.1%+3.6%
5Y3.4%-0.2%+3.6%
10Y3.0%0.1%+2.9%
1.1.3. Return on Equity

Shows how efficient Mega Lifesciences Public Company Limited is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Mega Lifesciences Public Company Limited to the Drug Manufacturers-Specialty & Generic industry mean.
  • 6.7% Return on Equity means Mega Lifesciences Public Company Limited generated ฿0.07 for each ฿1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Mega Lifesciences Public Company Limited:

  • The MRQ is 6.7%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 7.1%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ6.7%TTM7.1%-0.4%
TTM7.1%YOY5.7%+1.4%
TTM7.1%5Y5.7%+1.4%
5Y5.7%10Y5.4%+0.3%
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ6.7%0.6%+6.1%
TTM7.1%0.4%+6.7%
YOY5.7%0.4%+5.3%
5Y5.7%-0.3%+6.0%
10Y5.4%0.1%+5.3%

1.2. Operating Efficiency of Mega Lifesciences Public Company Limited.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Mega Lifesciences Public Company Limited is operating .

  • Measures how much profit Mega Lifesciences Public Company Limited makes for each ฿1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Mega Lifesciences Public Company Limited to the Drug Manufacturers-Specialty & Generic industry mean.
  • An Operating Margin of 15.3% means the company generated ฿0.15  for each ฿1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Mega Lifesciences Public Company Limited:

  • The MRQ is 15.3%. The company is operating efficient. +1
  • The TTM is 16.8%. The company is operating efficient. +1
Trends
Current periodCompared to+/- 
MRQ15.3%TTM16.8%-1.5%
TTM16.8%YOY14.5%+2.2%
TTM16.8%5Y14.7%+2.1%
5Y14.7%10Y8.5%+6.2%
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ15.3%2.5%+12.8%
TTM16.8%1.6%+15.2%
YOY14.5%2.7%+11.8%
5Y14.7%1.8%+12.9%
10Y8.5%0.8%+7.7%
1.2.2. Operating Ratio

Measures how efficient Mega Lifesciences Public Company Limited is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers-Specialty & Generic industry mean).
  • An Operation Ratio of 1.42 means that the operating costs are ฿1.42 for each ฿1 in net sales.

Let's take a look of the Operating Ratio trends of Mega Lifesciences Public Company Limited:

  • The MRQ is 1.424. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.400. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.424TTM1.400+0.024
TTM1.400YOY1.456-0.056
TTM1.4005Y1.431-0.030
5Y1.43110Y1.074+0.356
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4241.473-0.049
TTM1.4001.456-0.056
YOY1.4561.398+0.058
5Y1.4311.374+0.057
10Y1.0741.191-0.117

1.3. Liquidity of Mega Lifesciences Public Company Limited.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Mega Lifesciences Public Company Limited is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers-Specialty & Generic industry mean).
  • A Current Ratio of 1.85 means the company has ฿1.85 in assets for each ฿1 in short-term debts.

Let's take a look of the Current Ratio trends of Mega Lifesciences Public Company Limited:

  • The MRQ is 1.850. The company is able to pay all its short-term debts. +1
  • The TTM is 1.921. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.850TTM1.921-0.072
TTM1.921YOY1.836+0.086
TTM1.9215Y1.831+0.091
5Y1.83110Y1.083+0.747
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8501.880-0.030
TTM1.9211.901+0.020
YOY1.8362.112-0.276
5Y1.8312.182-0.351
10Y1.0831.891-0.808
1.3.2. Quick Ratio

Measures if Mega Lifesciences Public Company Limited is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Mega Lifesciences Public Company Limited to the Drug Manufacturers-Specialty & Generic industry mean.
  • A Quick Ratio of 0.75 means the company can pay off ฿0.75 for each ฿1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Mega Lifesciences Public Company Limited:

  • The MRQ is 0.755. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.713. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.755TTM0.713+0.041
TTM0.713YOY0.672+0.041
TTM0.7135Y0.770-0.057
5Y0.77010Y0.773-0.003
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7550.733+0.022
TTM0.7130.796-0.083
YOY0.6720.808-0.136
5Y0.7700.834-0.064
10Y0.7730.821-0.048

1.4. Solvency of Mega Lifesciences Public Company Limited.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Mega Lifesciences Public Company Limited assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Mega Lifesciences Public Company Limited to Drug Manufacturers-Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.41 means that Mega Lifesciences Public Company Limited assets are financed with 41.3% credit (debt) and the remaining percentage (100% - 41.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Mega Lifesciences Public Company Limited:

  • The MRQ is 0.413. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.395. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.413TTM0.395+0.018
TTM0.395YOY0.391+0.004
TTM0.3955Y0.401-0.006
5Y0.40110Y0.430-0.029
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4130.437-0.024
TTM0.3950.424-0.029
YOY0.3910.398-0.007
5Y0.4010.398+0.003
10Y0.4300.401+0.029
1.4.2. Debt to Equity Ratio

Measures if Mega Lifesciences Public Company Limited is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Mega Lifesciences Public Company Limited to the Drug Manufacturers-Specialty & Generic industry mean.
  • A Debt to Equity ratio of 70.3% means that company has ฿0.70 debt for each ฿1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Mega Lifesciences Public Company Limited:

  • The MRQ is 0.703. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.655. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.703TTM0.655+0.048
TTM0.655YOY0.646+0.008
TTM0.6555Y0.672-0.017
5Y0.67210Y0.792-0.121
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7030.652+0.051
TTM0.6550.675-0.020
YOY0.6460.623+0.023
5Y0.6720.684-0.012
10Y0.7920.697+0.095

2. Market Valuation of Mega Lifesciences Public Company Limited

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ฿1 in earnings Mega Lifesciences Public Company Limited generates.

  • Above 15 is considered overpriced but always compare Mega Lifesciences Public Company Limited to the Drug Manufacturers-Specialty & Generic industry mean.
  • A PE ratio of 77.31 means the investor is paying ฿77.31 for every ฿1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Mega Lifesciences Public Company Limited:

  • The EOD is 70.422. Neutral. Compare to industry.
  • The MRQ is 77.311. Neutral. Compare to industry.
  • The TTM is 75.446. Neutral. Compare to industry.
Trends
Current periodCompared to+/- 
EOD70.422MRQ77.311-6.889
MRQ77.311TTM75.446+1.865
TTM75.446YOY79.296-3.851
TTM75.4465Y93.888-18.442
5Y93.88810Y93.280+0.607
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
EOD70.422-0.124+70.546
MRQ77.311-0.437+77.748
TTM75.446-0.102+75.548
YOY79.29615.340+63.956
5Y93.8887.916+85.972
10Y93.2807.700+85.580
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Mega Lifesciences Public Company Limited.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Mega Lifesciences Public Company Limited:

  • The MRQ is -989.893. Very Bad. -2
  • The TTM is -157.241. Very Bad. -2
Trends
Current periodCompared to+/- 
MRQ-989.893TTM-157.241-832.651
TTM-157.241YOY256.388-413.629
TTM-157.2415Y-134.475-22.766
5Y-134.47510Y-107.048-27.427
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ-989.8930.012-989.905
TTM-157.2410.010-157.251
YOY256.3880.004+256.384
5Y-134.4750.010-134.485
10Y-107.0480.021-107.069

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Mega Lifesciences Public Company Limited is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers-Specialty & Generic industry mean).
  • A PB ratio of 5.18 means the investor is paying ฿5.18 for each ฿1 in book value.

Let's take a look of the Price to Book Ratio trends of Mega Lifesciences Public Company Limited:

  • The EOD is 4.720. Neutral. Compare to industry.
  • The MRQ is 5.182. Seems overpriced? -1
  • The TTM is 5.272. Seems overpriced? -1
Trends
Current periodCompared to+/- 
EOD4.720MRQ5.182-0.462
MRQ5.182TTM5.272-0.090
TTM5.272YOY4.410+0.862
TTM5.2725Y5.138+0.134
5Y5.13810Y4.248+0.890
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
EOD4.7201.415+3.305
MRQ5.1821.586+3.596
TTM5.2722.019+3.253
YOY4.4102.230+2.180
5Y5.1381.895+3.243
10Y4.2481.505+2.743
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Mega Lifesciences Public Company Limited compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.1410.332-143%0.238-159%0.206-169%0.250-157%
Book Value Growth--0.9710.9720%0.9720%0.9720%0.9720%
Book Value Per Share--9.7459.358+4%8.113+20%7.427+31%5.868+66%
Book Value Per Share Growth---0.0150.035-141%0.029-149%0.026-155%0.038-139%
Current Ratio--1.8501.921-4%1.836+1%1.831+1%1.083+71%
Debt To Asset Ratio--0.4130.395+5%0.391+6%0.401+3%0.430-4%
Debt To Equity Ratio--0.7030.655+7%0.646+9%0.672+5%0.792-11%
Dividend Per Share--0.8610.345+149%0.225+283%0.279+209%0.269+220%
Dividend Per Share Growth--0.999-2977.531+298118%-19584.847+1960329%-4951.268+495668%-3904.200+390868%
Eps--0.6530.657-1%0.461+42%0.430+52%0.317+106%
Eps Growth---0.0780.014-657%0.093-184%-0.003-96%-0.0780%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Net Profit Margin--0.1450.153-5%0.116+25%0.120+21%0.103+41%
Operating Margin--0.1530.168-9%0.145+5%0.147+4%0.085+80%
Operating Ratio--1.4241.400+2%1.456-2%1.4310%1.074+33%
Pb Ratio4.720-10%5.1825.272-2%4.410+17%5.138+1%4.248+22%
Pe Ratio70.422-10%77.31175.446+2%79.296-3%93.888-18%93.280-17%
Peg Ratio---989.893-157.241-84%256.388-486%-134.475-86%-107.048-89%
Price Per Share46.000-10%50.50049.125+3%35.750+41%37.635+34%27.063+87%
Price To Total Gains Ratio63.925-10%70.17872.845-4%79.407-12%100.912-30%99.674-30%
Profit Growth--96.89597.1600%97.387-1%97.1110%96.9220%
Quick Ratio--0.7550.713+6%0.672+12%0.770-2%0.773-2%
Return On Assets--0.0390.043-8%0.035+14%0.034+15%0.030+30%
Return On Equity--0.0670.071-5%0.057+18%0.057+17%0.054+24%
Revenue Growth--0.9720.972+0%0.9730%0.972+0%0.972+0%
Total Gains Per Share--0.7200.677+6%0.463+55%0.485+48%0.519+39%
Total Gains Per Share Growth--0.0510.053-4%-0.097+290%-0.220+530%-1.770+3566%
Usd Book Value--244698105.600234974844.000+4%203719766.400+20%186549602.400+31%147388050.166+66%
Usd Book Value Change Per Share---0.0040.010-143%0.007-159%0.006-169%0.007-157%
Usd Book Value Per Share--0.2810.270+4%0.234+20%0.214+31%0.169+66%
Usd Dividend Per Share--0.0250.010+149%0.006+283%0.008+209%0.008+220%
Usd Eps--0.0190.019-1%0.013+42%0.012+52%0.009+106%
Usd Price Per Share1.325-10%1.4541.415+3%1.030+41%1.084+34%0.779+87%
Usd Profit--16401974.40016505956.800-1%11571487.200+42%10797023.520+52%7950840.148+106%
Usd Revenue--113179536.000108147074.400+5%98955504.000+14%88086290.400+28%73103333.538+55%
Usd Total Gains Per Share--0.0210.020+6%0.013+55%0.014+48%0.015+39%
 EOD+3 -2MRQTTM+14 -21YOY+23 -125Y+23 -1210Y+24 -11

3.2. Fundamental Score

Let's check the fundamental score of Mega Lifesciences Public Company Limited based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1570.422
Price to Book Ratio (EOD)Between0-14.720
Net Profit Margin (MRQ)Greater than00.145
Operating Margin (MRQ)Greater than00.153
Quick Ratio (MRQ)Greater than10.755
Current Ratio (MRQ)Greater than11.850
Debt to Asset Ratio (MRQ)Less than10.413
Debt to Equity Ratio (MRQ)Less than10.703
Return on Equity (MRQ)Greater than0.150.067
Return on Assets (MRQ)Greater than0.050.039
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of Mega Lifesciences Public Company Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5050.683
Ma 20Greater thanMa 5045.725
Ma 50Greater thanMa 10045.725
Ma 100Greater thanMa 20047.625
OpenGreater thanClose46.500
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2022-06-30. Currency in THB. All numbers in thousands.

Summary
Total Assets14,470,549
Total Liabilities5,974,087
Total Stockholder Equity8,496,324
 As reported
Total Liabilities 5,974,087
Total Stockholder Equity+ 8,496,324
Total Assets = 14,470,549

Assets

Total Assets14,470,549
Total Current Assets10,340,694
Long-term Assets10,340,694
Total Current Assets
Cash And Cash Equivalents 2,119,941
Short-term Investments 335,412
Net Receivables 3,882,582
Inventory 3,864,314
Other Current Assets 138,445
Total Current Assets  (as reported)10,340,694
Total Current Assets  (calculated)10,340,694
+/-0
Long-term Assets
Property Plant Equipment 2,194,061
Goodwill 488,673
Long Term Investments 226,777
Intangible Assets 874,821
Other Assets 345,523
Long-term Assets  (as reported)4,129,855
Long-term Assets  (calculated)4,129,855
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities5,590,429
Long-term Liabilities383,658
Total Stockholder Equity8,496,324
Total Current Liabilities
Short Long Term Debt 187,522
Accounts payable 2,744,970
Other Current Liabilities 1,783,923
Total Current Liabilities  (as reported)5,590,429
Total Current Liabilities  (calculated)4,716,415
+/- 874,014
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt191,643
Other Liabilities 278,194
Long-term Liabilities  (as reported)383,658
Long-term Liabilities  (calculated)469,837
+/- 86,179
Total Stockholder Equity
Common Stock435,935
Retained Earnings 6,213,621
Total Stockholder Equity (as reported)8,496,324
Total Stockholder Equity (calculated)6,649,556
+/- 1,846,768
Other
Capital Stock435,935
Common Stock Shares Outstanding 871,870
Net Invested Capital 8,683,846
Net Tangible Assets 7,132,830
Net Working Capital 4,750,265



Balance Sheet

Currency in THB. All numbers in thousands.

 Trend2022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312011-12-31
> Total Assets 
3,227,649
4,135,256
4,491,874
4,883,636
5,147,679
6,535,853
6,874,311
6,547,117
6,524,934
6,722,439
6,736,356
7,009,635
7,255,245
7,612,547
7,338,548
7,328,173
7,471,991
7,940,973
7,815,990
8,222,537
8,326,657
8,719,842
8,476,532
8,768,418
8,602,250
9,632,593
9,972,396
10,092,140
10,191,281
10,532,705
11,189,919
11,325,857
11,693,640
11,589,714
11,430,970
11,733,793
12,548,005
13,271,700
13,639,790
14,470,549
14,470,54913,639,79013,271,70012,548,00511,733,79311,430,97011,589,71411,693,64011,325,85711,189,91910,532,70510,191,28110,092,1409,972,3969,632,5938,602,2508,768,4188,476,5328,719,8428,326,6578,222,5377,815,9907,940,9737,471,9917,328,1737,338,5487,612,5477,255,2457,009,6356,736,3566,722,4396,524,9346,547,1176,874,3116,535,8535,147,6794,883,6364,491,8744,135,2563,227,649
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,688,893
5,601,599
6,048,110
5,821,096
6,470,143
6,187,528
6,352,813
6,268,947
6,468,614
6,900,413
6,956,848
6,974,404
7,245,836
7,230,612
7,318,963
7,603,887
7,619,823
7,380,400
7,720,951
8,568,085
9,300,879
9,620,392
10,340,694
10,340,6949,620,3929,300,8798,568,0857,720,9517,380,4007,619,8237,603,8877,318,9637,230,6127,245,8366,974,4046,956,8486,900,4136,468,6146,268,9476,352,8136,187,5286,470,1435,821,0966,048,1105,601,5995,688,89300000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
565,856
518,364
692,124
476,525
477,671
712,145
468,966
442,110
559,532
610,485
846,762
1,078,264
1,247,922
998,011
1,038,747
979,423
1,006,451
1,490,461
1,484,882
1,631,935
2,197,692
2,240,723
2,119,941
2,119,9412,240,7232,197,6921,631,9351,484,8821,490,4611,006,451979,4231,038,747998,0111,247,9221,078,264846,762610,485559,532442,110468,966712,145477,671476,525692,124518,364565,85600000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
675,556
650,938
673,834
477,559
714,328
731,076
708,423
666,964
381,405
574,473
574,473
236,922
207,142
211,091
211,091
211,091
211,091
371,267
333,660
333,660
333,660
335,412
335,412
335,412335,412333,660333,660333,660371,267211,091211,091211,091211,091207,142236,922574,473574,473381,405666,964708,423731,076714,328477,559673,834650,938675,55600000000000000000
       Net Receivables 
1,425,917
1,208,902
1,305,728
1,681,743
1,747,616
1,788,962
1,892,355
1,858,257
2,110,260
2,201,598
2,331,539
2,532,195
2,396,768
2,306,436
2,317,275
2,135,370
2,092,116
2,287,349
2,149,426
2,292,921
2,420,078
2,615,878
2,238,139
2,598,023
2,485,083
2,638,190
2,436,470
2,345,270
2,419,472
2,616,400
2,938,159
2,748,106
2,703,804
2,581,435
2,187,762
2,534,839
2,962,725
2,721,433
3,186,344
3,882,582
3,882,5823,186,3442,721,4332,962,7252,534,8392,187,7622,581,4352,703,8042,748,1062,938,1592,616,4002,419,4722,345,2702,436,4702,638,1902,485,0832,598,0232,238,1392,615,8782,420,0782,292,9212,149,4262,287,3492,092,1162,135,3702,317,2752,306,4362,396,7682,532,1952,331,5392,201,5982,110,2601,858,2571,892,3551,788,9621,747,6161,681,7431,305,7281,208,9021,425,917
       Other Current Assets 
168,683
160,515
75,489
73,747
68,751
189,605
105,605
115,422
89,783
185,168
138,587
120,444
154,491
305,889
161,701
177,252
154,252
254,530
177,809
216,184
175,107
442,574
234,775
200,457
197,524
254,894
14,390
16,783
19,730
255,295
290,123
177,230
165,152
287,462
286,278
275,046
215,372
162,799
130,315
138,445
138,445130,315162,799215,372275,046286,278287,462165,152177,230290,123255,29519,73016,78314,390254,894197,524200,457234,775442,574175,107216,184177,809254,530154,252177,252161,701305,889154,491120,444138,587185,16889,783115,422105,605189,60568,75173,74775,489160,515168,683
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,071,983
3,135,292
3,216,877
3,286,829
3,959,307
4,006,894
4,089,753
3,969,891
4,050,570
4,012,842
3,979,920
3,970,821
4,019,398
4,129,855
4,129,8554,019,3983,970,8213,979,9204,012,8424,050,5703,969,8914,089,7534,006,8943,959,3073,286,8293,216,8773,135,2923,071,98300000000000000000000000000
       Property Plant Equipment 
368,464
731,847
810,732
853,159
921,275
969,508
1,002,486
1,012,916
987,506
980,141
978,247
991,238
1,013,573
1,031,495
1,019,629
1,192,593
1,169,257
1,164,284
1,142,178
1,117,349
1,193,308
1,183,037
1,233,595
1,274,290
1,260,438
1,425,989
1,544,455
1,635,074
1,693,559
1,770,592
2,222,409
2,194,696
2,307,840
2,213,797
2,236,784
2,176,368
2,081,560
2,102,739
2,174,003
2,194,061
2,194,0612,174,0032,102,7392,081,5602,176,3682,236,7842,213,7972,307,8402,194,6962,222,4091,770,5921,693,5591,635,0741,544,4551,425,9891,260,4381,274,2901,233,5951,183,0371,193,3081,117,3491,142,1781,164,2841,169,2571,192,5931,019,6291,031,4951,013,573991,238978,247980,141987,5061,012,9161,002,486969,508921,275853,159810,732731,847368,464
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
153,581
149,879
215,654
215,221
219,472
220,498
223,610
213,130
212,585
212,443
202,332
199,032
199,421
427,829
435,815
442,296
437,318
443,866
453,717
481,095
476,253
480,300
488,673
488,673480,300476,253481,095453,717443,866437,318442,296435,815427,829199,421199,032202,332212,443212,585213,130223,610220,498219,472215,221215,654149,879153,58100000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,918
4,844
4,424
206,795
4,229
3,657
76,566
75,390
461,871
258,363
248,582
245,226
240,568
258,008
240,521
205,213
194,469
202,617
206,956
218,530
214,789
213,941
226,777
226,777213,941214,789218,530206,956202,617194,469205,213240,521258,008240,568245,226248,582258,363461,87175,39076,5663,6574,229206,7954,4244,8444,91800000000000000000
       Intangible Assets 
5,679
8,926
15,652
20,816
209,504
213,016
217,469
221,322
223,653
230,211
232,417
234,704
234,627
232,700
231,414
239,059
239,262
736,055
720,621
729,649
724,488
733,843
735,622
527,007
512,310
806,132
805,378
794,025
791,346
792,128
864,888
861,304
878,093
874,999
883,104
863,304
885,722
876,886
868,475
874,821
874,821868,475876,886885,722863,304883,104874,999878,093861,304864,888792,128791,346794,025805,378806,132512,310527,007735,622733,843724,488729,649720,621736,055239,262239,059231,414232,700234,627234,704232,417230,211223,653221,322217,469213,016209,50420,81615,6528,9265,679
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
25,064
23,701
39,509
25,607
15,769
84,904
29,162
40,048
53,533
72,577
69,178
53,513
33,489
40,996
40,99633,48953,51369,17872,57753,53340,04829,16284,90415,76925,60739,50923,70125,06400000000000000000000000000
> Total Liabilities 
1,971,379
2,509,015
2,724,380
3,144,588
3,293,727
2,843,280
3,120,408
2,818,268
2,799,293
2,744,177
2,699,283
2,992,226
3,203,284
3,277,879
2,876,442
2,870,863
3,075,611
3,261,163
2,987,757
3,313,800
3,447,798
3,475,446
3,020,429
3,323,471
3,307,660
3,908,251
3,951,451
4,272,286
4,395,715
4,357,609
4,932,811
4,819,135
5,037,854
4,610,790
4,109,739
4,395,322
5,053,997
5,246,579
5,019,986
5,974,087
5,974,0875,019,9865,246,5795,053,9974,395,3224,109,7394,610,7905,037,8544,819,1354,932,8114,357,6094,395,7154,272,2863,951,4513,908,2513,307,6603,323,4713,020,4293,475,4463,447,7983,313,8002,987,7573,261,1633,075,6112,870,8632,876,4423,277,8793,203,2842,992,2262,699,2832,744,1772,799,2932,818,2683,120,4082,843,2803,293,7273,144,5882,724,3802,509,0151,971,379
   > Total Current Liabilities 
1,899,461
2,091,435
2,324,947
2,693,182
2,820,360
2,547,407
2,840,884
2,554,205
2,552,224
2,511,426
2,484,835
2,788,011
2,987,143
3,095,241
2,721,683
2,735,763
2,966,860
3,152,888
2,879,212
3,205,633
3,338,753
3,366,226
2,906,146
3,202,914
3,178,282
3,774,942
3,816,270
4,097,134
4,213,590
4,158,166
4,584,518
4,455,549
4,667,099
4,261,663
3,706,119
3,992,325
4,659,291
4,853,355
4,624,525
5,590,429
5,590,4294,624,5254,853,3554,659,2913,992,3253,706,1194,261,6634,667,0994,455,5494,584,5184,158,1664,213,5904,097,1343,816,2703,774,9423,178,2823,202,9142,906,1463,366,2263,338,7533,205,6332,879,2123,152,8882,966,8602,735,7632,721,6833,095,2412,987,1432,788,0112,484,8352,511,4262,552,2242,554,2052,840,8842,547,4072,820,3602,693,1822,324,9472,091,4351,899,461
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
669,708
445,985
735,712
674,993
512,169
311,530
618,166
0
0
946,229
1,226,396
1,165,943
888,306
0
0
0
0
0
0
0
0
0
0
0000000000888,3061,165,9431,226,396946,22900618,166311,530512,169674,993735,712445,985669,70800000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
669,708
445,985
735,712
674,993
512,169
311,530
618,166
0
0
946,229
1,226,396
1,165,943
888,306
795,949
1,081,193
796,069
499,491
259,246
203,238
156,189
168,176
113,554
187,522
187,522113,554168,176156,189203,238259,246499,491796,0691,081,193795,949888,3061,165,9431,226,396946,22900618,166311,530512,169674,993735,712445,985669,70800000000000000000
       Accounts payable 
787,145
768,912
883,141
896,605
1,076,285
1,144,738
1,452,560
1,255,448
1,204,377
1,403,926
1,410,209
1,354,696
1,513,359
1,604,214
1,313,020
1,346,849
1,519,833
1,518,603
1,434,242
1,441,047
1,559,850
1,598,159
1,513,623
1,575,404
1,564,114
1,690,770
1,713,519
1,703,818
1,816,502
2,019,591
1,973,590
1,943,201
2,448,183
2,047,757
1,794,744
2,235,361
2,665,863
2,526,618
2,269,949
2,744,970
2,744,9702,269,9492,526,6182,665,8632,235,3611,794,7442,047,7572,448,1831,943,2011,973,5902,019,5911,816,5021,703,8181,713,5191,690,7701,564,1141,575,4041,513,6231,598,1591,559,8501,441,0471,434,2421,518,6031,519,8331,346,8491,313,0201,604,2141,513,3591,354,6961,410,2091,403,9261,204,3771,255,4481,452,5601,144,7381,076,285896,605883,141768,912787,145
       Other Current Liabilities 
379,321
471,055
498,736
587,580
522,397
617,978
553,343
478,000
531,236
677,722
634,734
837,536
846,755
856,793
980,993
755,237
828,827
971,192
1,003,032
1,030,496
1,103,910
1,255,898
1,080,993
550,933
376,277
244,032
637,145
591,455
646,232
334,447
1,183,601
872,432
747,858
849,307
916,068
865,612
909,722
818,874
1,442,486
1,783,923
1,783,9231,442,486818,874909,722865,612916,068849,307747,858872,4321,183,601334,447646,232591,455637,145244,032376,277550,9331,080,9931,255,8981,103,9101,030,4961,003,032971,192828,827755,237980,993856,793846,755837,536634,734677,722531,236478,000553,343617,978522,397587,580498,736471,055379,321
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
135,181
175,152
182,125
199,443
348,293
363,586
370,755
349,127
403,620
402,997
394,706
393,224
395,461
383,658
383,658395,461393,224394,706402,997403,620349,127370,755363,586348,293199,443182,125175,152135,18100000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-669,708
-445,985
-735,712
-674,993
-512,169
-311,530
-618,166
0
0
-943,083
-1,223,639
-1,163,521
-886,136
170,959
172,385
167,586
147,976
210,091
209,853
194,457
188,153
184,134
191,643
191,643184,134188,153194,457209,853210,091147,976167,586172,385170,959-886,136-1,163,521-1,223,639-943,08300-618,166-311,530-512,169-674,993-735,712-445,985-669,70800000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
112
0
0
332
72
0
0
0
0
0
000007233200112000000000000000000000000000000
> Total Stockholder Equity
1,233,623
1,602,859
1,746,596
1,718,548
1,853,928
3,692,561
3,753,926
3,728,901
3,725,658
3,978,280
4,037,106
4,017,427
4,051,961
4,334,690
4,462,024
4,457,267
4,396,374
4,679,804
4,828,204
4,908,718
4,878,825
5,244,361
5,456,064
5,444,903
5,294,516
5,724,254
6,020,800
5,819,748
5,795,471
6,174,998
6,235,502
6,482,492
6,633,448
6,957,637
7,299,783
7,317,098
7,468,950
8,002,820
8,599,557
8,496,324
8,496,3248,599,5578,002,8207,468,9507,317,0987,299,7836,957,6376,633,4486,482,4926,235,5026,174,9985,795,4715,819,7486,020,8005,724,2545,294,5165,444,9035,456,0645,244,3614,878,8254,908,7184,828,2044,679,8044,396,3744,457,2674,462,0244,334,6904,051,9614,017,4274,037,1063,978,2803,725,6583,728,9013,753,9263,692,5611,853,9281,718,5481,746,5961,602,8591,233,623
   Retained Earnings 
1,262,105
1,672,858
1,878,527
1,524,381
1,658,602
1,261,814
1,317,548
1,290,639
1,315,384
1,566,320
1,672,307
1,621,487
1,635,540
1,912,249
2,026,221
2,036,637
2,005,522
2,300,491
2,492,213
2,575,199
2,561,632
2,947,173
3,204,039
3,145,378
3,131,610
3,540,077
3,711,064
3,583,641
3,595,489
4,041,212
3,988,740
4,292,099
4,320,252
4,751,586
5,085,134
5,118,602
5,276,336
5,766,336
6,379,828
6,213,621
6,213,6216,379,8285,766,3365,276,3365,118,6025,085,1344,751,5864,320,2524,292,0993,988,7404,041,2123,595,4893,583,6413,711,0643,540,0773,131,6103,145,3783,204,0392,947,1732,561,6322,575,1992,492,2132,300,4912,005,5222,036,6372,026,2211,912,2491,635,5401,621,4871,672,3071,566,3201,315,3841,290,6391,317,5481,261,8141,658,6021,524,3811,878,5271,672,8581,262,105
   Accumulated Other Comprehensive Income 0000000000000000000000000000000000000000
   Capital Surplus 0000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000



Balance Sheet

Currency in THB. All numbers in thousands.




Cash Flow

Currency in THB. All numbers in thousands.




Income Statement

Currency in THB. All numbers in thousands.


Latest Income Statement (annual, 2021-12-31)

Gross Profit (+$)
totalRevenue14,135,656
Cost of Revenue-8,224,859
Gross Profit5,910,7975,910,797
 
Operating Income (+$)
Gross Profit5,910,797
Operating Expense-11,994,212
Operating Income2,141,444-6,083,415
 
Operating Expense (+$)
Research Development40,521
Selling General Administrative3,611,607
Selling And Marketing Expenses-
Operating Expense11,994,2123,652,128
 
Net Interest Income (+$)
Interest Income-
Interest Expense-28,275
Net Interest Income-28,275-28,275
 
Pretax Income (+$)
Operating Income2,141,444
Net Interest Income-28,275
Other Non-Operating Income Expenses-
Income Before Tax (EBT)2,276,8811,977,732
EBIT - interestExpense = 2,149,842
2,282,849
1,975,100
Interest Expense28,275
Earnings Before Interest and Taxes (ebit)2,178,1172,305,156
Earnings Before Interest and Taxes (ebitda)2,579,592
 
After tax Income (+$)
Income Before Tax2,276,881
Tax Provision-336,024
Net Income From Continuing Ops1,940,8571,940,857
Net Income1,946,825
Net Income Applicable To Common Shares1,946,825
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net163,71228,275
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications
ZENSARTECH.NSE
29 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of ZENSARTECH.NSE.

ZENSARTECH.NSE Daily Candlestick Chart
MBECL.NSE
31 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of MBECL.NSE.

MBECL.NSE Daily Candlestick Chart
HDFCMFGETF.NSE
34 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of HDFCMFGETF.NSE.

HDFCMFGETF.NSE Daily Candlestick Chart
GOLDSHARE.NSE
34 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of GOLDSHARE.NSE.

GOLDSHARE.NSE Daily Candlestick Chart
GOACARBON.NSE
34 minutes ago

I found you a RSI Bearish Reversal Divergence on the daily chart of GOACARBON.NSE.

GOACARBON.NSE Daily Candlestick Chart
BCOMSITR.INDX
37 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of BCOMSITR.INDX.

BCOMSITR.INDX Daily Candlestick Chart
BCOMSI.INDX
37 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of BCOMSI.INDX.

BCOMSI.INDX Daily Candlestick Chart
BCOMPR.INDX
37 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of BCOMPR.INDX.

BCOMPR.INDX Daily Candlestick Chart
VXN.INDX
39 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of VXN.INDX.

VXN.INDX Daily Candlestick Chart
VX.INDX
39 minutes ago

I found you a Death Cross on the daily chart of VX.INDX.

VX.INDX Daily Candlestick Chart
RVX.INDX
40 minutes ago

I found you a Death Cross on the daily chart of RVX.INDX.

RVX.INDX Daily Candlestick Chart
NBI.INDX
40 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of NBI.INDX.

NBI.INDX Daily Candlestick Chart
DJUSST.INDX
41 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of DJUSST.INDX.

DJUSST.INDX Daily Candlestick Chart
CACTN.INDX
42 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of CACTN.INDX.

CACTN.INDX Daily Candlestick Chart
CACTR.INDX
42 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of CACTR.INDX.

CACTR.INDX Daily Candlestick Chart
BSPT.INDX
42 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of BSPT.INDX.

BSPT.INDX Daily Candlestick Chart
VBL.BSE
43 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of VBL.BSE.

VBL.BSE Daily Candlestick Chart
LOYAL.BSE
47 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of LOYAL.BSE.

LOYAL.BSE Daily Candlestick Chart
TWL.BSE
47 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of TWL.BSE.

TWL.BSE Daily Candlestick Chart
SSLFINANCE.BSE
50 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of SSLFINANCE.BSE.

SSLFINANCE.BSE Daily Candlestick Chart
ESCORTSFIN.BSE
51 minutes ago

I found you a RSI Bullish Reversal Divergence on the daily chart of ESCORTSFIN.BSE.

ESCORTSFIN.BSE Daily Candlestick Chart
WAA.BSE
53 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of WAA.BSE.

WAA.BSE Daily Candlestick Chart
TRL.BSE
53 minutes ago

I found you a MACD Bearish Reversal Divergence on the daily chart of TRL.BSE.

TRL.BSE Daily Candlestick Chart
ANGEL.BSE
53 minutes ago

I found you a STOCH Bearish Hidden Divergence on the daily chart of ANGEL.BSE.

ANGEL.BSE Daily Candlestick Chart
THEMISMED.BSE
55 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of THEMISMED.BSE.

THEMISMED.BSE Daily Candlestick Chart